Will the use of basket therapies mean certain SSA listings criteria will become less relevant? For example, basket clinical trials have had remarkable success. The drugs and drug combinations they test have shown remarkable success managing cancers that doctors consider inoperable or unresectable. Are current SSA listings requiring a cancer to be inoperable or unresectable still relevant if drugs that target the cancer’s genetic profile effectively stabilize and manage the person’s disease?
Idea No. 81